Feature

Fighting back against psoriasis bullies

Publish date: November 23, 2016

 

Pages

Recommended Reading

Psoriasis not consistently linked to adverse pregnancy outcomes
MDedge Family Medicine
Birth outcomes unaffected by paternal immunosuppressive therapy
MDedge Family Medicine
Guselkumab achieves highest-ever response rates in psoriasis
MDedge Family Medicine
Secukinumab for psoriasis at 4 years: undiminished efficacy and safety
MDedge Family Medicine
Tildrakizumab for psoriasis scores high marks in phase III
MDedge Family Medicine
Include quality of life measures in evaluating treatment success of psoriasis
MDedge Family Medicine
FDA: Etanercept first biologic approved for pediatric psoriasis
MDedge Family Medicine
Study offers reassuring data on certolizumab use in pregnancy
MDedge Family Medicine
Infliximab biosimilar posts mostly reassuring data in Norway’s NOR-SWITCH study
MDedge Family Medicine
Pediatric psoriasis linked to multiple psychiatric comorbidities
MDedge Family Medicine